Journal of Periodontal and Implant Science

Korean Academy of Periodontology (대한치주과학회)
권호 표지

Antimicrobial effect of cefixime on 6 species of periodotopathogens

Cefixime의 치주병원성 세균 6종에 대한 항균 효과

  • Jang, Hyun-Seon (Dept. of Periodontology, College of Dentistry, Chosun University, Oral Biology Research Institute, Chosun University) ;
  • Park, Mun-Gyu (Dept. of Periodontology, College of Dentistry, Chosun University) ;
  • Kook, Joong-Ki (Dept. of Oral Biochemistry, College of Dentistry, Chosun University, Oral Biology Research Institute, Chosun University) ;
  • Kim, Hwa-Sook (Dept. of Oral Biochemistry, College of Dentistry, Chosun University) ;
  • Kim, Byung-Ock (Dept. of Periodontology, College of Dentistry, Chosun University, Oral Biology Research Institute, Chosun University)
  • 장현선 (조선대학교 치과대학 치주과학 교실, 조선대학교 치과대학 구강생물학연구소) ;
  • 박문규 (조선대학교 치과대학 치주과학 교실) ;
  • 국중기 (조선대학교 치과대학 구강생화학 교실, 조선대학교 치과대학 구강생물학연구소) ;
  • 김화숙 (조선대학교 치과대학 구강생화학 교실) ;
  • 김병옥 (조선대학교 치과대학 치주과학 교실, 조선대학교 치과대학 구강생물학연구소)
  • Published : 2005.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

The aim of this study was to determine the minimal inhibitory concentration(MIC) of cefixime, which is a 3rd generation of cefalosporin, against 6 species of putative periodontopathogens; Fusobacterium nucleatum, Actinobacillus actinomycetemcomitans, Prevotella intermedia, Prevotella nigrescens, Tannerella forsythia and Porphyromonas gingivalis. The efficacy of cefixime was examined by comparing it with that of several antibiotics(amoxicillin, $Augmentin^{(R)}$ ciprofloxacin, metronidazole, and tetracycline), which were used as the control. The MIC was measured using a microdilution method. The MIC of cefixime against the putative periodotopathogens, as a single use regimen, was relatively lower than that of the other antibiotics. The MIC of cefixime/metronidazole against P. intermedia ChDC KB14, P. nigrescens ChDC KB50, F. nucleatum ChDC PV-F37, F. nucleatum ChDC F130, and F. nucleatum ChDC F175, as a simultaneous regimen, was lower than that of the other antibiotics. The concentration of cefixime in the crevicular fluid of volunteers who received 250mg every 12 hours for 3 days was $9{\mu}g/ml$ after 9 hours. In conclusion, cefixime showed good antimicrobial activity in a single treatment or as a combined therapy with amoxicillin, $Augmentin^{(R)}$ or metronidazole against 6 periodontopathogens.

Keywords

References

  1. Sirinian G, Shimizu T, Sugar C, Slots J, Chen C. Periodontopathic bacteria in young healthy subjects of different ethnic backgrounds in los angeles. J periodontol 2002;73:283-288 https://doi.org/10.1902/jop.2002.73.3.283
  2. Ali RW, Johannessen AC, Dahlen G, Socransky SS. Skaug N. Comparison of the subgingival microbiota of periodontally healthy and diseased adults in Northern Cameroon. J Clin Periodontol 1997 24;830-835 https://doi.org/10.1111/j.1600-051X.1997.tb01197.x
  3. Tanner A. Kent R. Maiden :MF, Taubman MA. Clinical. microbiological and immunological profile of healthy, gingivitis, and putative active periodontal subjects. J Periodont Res 1996;31:195-204 https://doi.org/10.1111/j.1600-0765.1996.tb00484.x
  4. 치주과교수협의회.: 치주과학, 4판, 군자출판사, 2004
  5. Sigusch B, Beier M. Klinger G, Pfister W, Glockmann E. A 2-step non-surgical procedure and systemic antibiotics in the treatment of rapidly progressive periodontitis. J periodontol 2001;72:275-283 https://doi.org/10.1902/jop.2001.72.3.275
  6. Purucker P, Mertes H Goodson JM. Bernimoulin JP. Local versus systemic adiuctive antibiotic therapy in 28 patients with generalized aggressive periodontitis. J periodontol 2001;72:1241-1245 https://doi.org/10.1902/jop.2000.72.9.1241
  7. Poulet PP, Duffaut D, Lodter JP. Metronidazole susceptibility testing of anaerobic bacteria associated with periodontal disease. J Clin Periodontol 1999; 26(4): 261-263 https://doi.org/10.1034/j.1600-051X.1999.260411.x
  8. Paiukanta R, Asikainen S, Saarela M, Alaluusua S, Jousimies-Somer H. In vitro antimicrobial susceptibility of different serotypes of Actinobacillus actinomyce-temcomitans. Scand J Dent Res 1993;101(5):299-303
  9. Haffaiee AD, Socransky SS, Dibart S, Kent RL. Response to periodontal therapy in patients with high or low levels of P. gingivalis. P. intermedia, P. nigrescens and B. forsythus. J Clin Periodontol 1996;23(4):336-345 https://doi.org/10.1111/j.1600-051X.1996.tb00555.x
  10. Eick S, Seltmann T, Pfister W. Efficacy of antibiotics to strains of periodonto-pathogenic bacteria within a single species biofilman in vitro study. J Clin Periodontol 2004;31(5):376-383 https://doi.org/10.1111/j.0303-6979.2004.00490.x
  11. Murray PR, Jorgensen JR. Quantitative susceptibility test methods in major united states medical center. Antimicrobial agent and chemotherapy 1981;20:66-70 https://doi.org/10.1128/AAC.20.1.66
  12. Gordon JM, Walker CB, Goodson JM, Socransky SS. Sensitivity assay for measuring tetracycline levels in gingival crevice fluid. Antimicrob Agents Chemother 1980;17:193-198 https://doi.org/10.1128/AAC.17.2.193
  13. van Winkelhoff, A., Rams, T.E., Slots, J. : Systemic antibiotic therapy in periodontitis. J Periodontol 2000. 1996;10:45-78 https://doi.org/10.1111/j.1600-0757.1996.tb00068.x
  14. Slot J, Rams TE. Antibiotics in periodontal therapy advantages and disadvantages. J Clin Periodontol 1990;17:479-493 https://doi.org/10.1111/j.1365-2710.1992.tb01220.x
  15. Paster BJ. Boches SK. Galvin JL, Ericson RE. Lau CN. Levanos VA. Sahasrabudhe A. Dewhirst FE. Bacterial diversity in human subgingival plaque. J Bacteriology 2001;12:3770-3783
  16. Walker, C.B. The acquisition of antibiotic resistance in the periodontal disease. Peridontol 2000. 1996;10:78-88
  17. Larsen T, Fiehn NE. Development of resistance to metronidazole and minocycline in vitro. J Clin Periodontol 1997;24(4):254-259 https://doi.org/10.1111/j.1600-051X.1997.tb01839.x
  18. Olsvik B. Tetracycline resistance in oral microorganisms in patients with periodontal disease. Nor Tannlaegeforen Tid 1991;101(2):50-52
  19. Fuchs PC. Jones RN. Barry AL. et al. In vitro evaluation of cefixime (FK027. FR17027. CL284635): spectrum against recent clinical isolates. comparative antimicrobial activity. beta-lactamase stability. and preliminary susceptibility testing criteria. Diagn Microbiol Infect Dis 1986;5(2):151-62 https://doi.org/10.1016/0732-8893(86)90117-3
  20. Barry AL. Jones RN. Cefixime: spectrum of antibacterial activity against 16.016 clinical isolates. Pediatr Infect Dis J 1987;6(10):954-947 https://doi.org/10.1097/00006454-198710000-00033
  21. Klepser :ME. Marangos MN. Patel KB. et al. Clinical pharmacokinetics of newer cephalosporins. Clin Pharmacokinet. 1995;28(5):361-384 https://doi.org/10.2165/00003088-199528050-00003
  22. Faulkner RD, Yacobi A, Barone JS, Kaplan SA, Silber BM. Pharmacokinetic profile of cefixime in man. Pediatr Infect Dis J 1987;6(10):963-970 https://doi.org/10.1097/00006454-198710000-00035
  23. Lehtonen L, Huovinen P. Susceptibility of respiratory tract pathogens in Finland to cefixime and nine other antimicrobial agents. Scand J Infect Dis 1993:25(3) :373-378 https://doi.org/10.3109/00365549309008513
  24. Lavy E, Ziv G, Aroch I, Glickman A. Clinical pharmacologic aspects of cefixime in dogs. Am J Vet Res 1995;6(5):633-638
  25. Choi JH, Seong JR, Kook JK, Kim DK. Comparison of cultural method and PCR method for the assay of tetracycline-resistant Fusobacterium nucleatum isolated in Korean. J Kor Acad Dent Health 2003;27(4):581-589
  26. Bokor-Bratic M, Brkanic T. Clinical use of tetracyclines in the treatment of periodontal diseases. Med Pregl 2000;53:266-271